Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 1999 April;40(2) > The Journal of Cardiovascular Surgery 1999 April;40(2):299-305





A Journal on Cardiac, Vascular and Thoracic Surgery

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632




The Journal of Cardiovascular Surgery 1999 April;40(2):299-305

language: English

Tumor mark­ers kinet­ic in malig­nant ­lung neo­plasms

Cristofori R., Aimo G. *, Mengozzi G. *, Oliaro A., Revello F. **, Rapellino M. **

From the Department of Thoracic Surgery S. Giovanni Battista Hospital, Turin, Italy University of Turin, Italy
* Clinical Chemistry Laboratory “Baldi e Riberi”
** Department of Pathophysiology and Bronchoscopy


Background. No stud­ies ­about cor­re­la­tion ­between post­op­er­a­tive ­half-­life of ­tumor mark­ers and prog­no­sis in ­lung can­cer ­exist in lit­er­a­ture. The aim of our ­study was to deter­mine the ­half-­life of CEA, TPA, NSE and CYFRA 21-1 in post­op­er­a­tive peri­od ­after sur­gery of bron­cho­gen­ic car­ci­no­ma, and to cor­re­late it ­with the prog­no­sis and sur­vi­val of the ­patients.
Methods. From March 1997 to March 1998, 35 ­patients ­with bron­cho­gen­ic car­ci­no­ma ­were stud­ied (29 ­males and 6 ­females, ­mean age 64.9 ­years, ­range 51-77 and 61.0 ­years, ­range 52-77 respec­tive­ly). The ­mean fol­low-up for ­males was 125.70 ­days (­from 30 to 198) ­after sur­gery and for ­females 125.79 ­days (­from 30 to 180). CEA and NSE ­were test­ed by immu­noen­zy­mat­ic auto­mat­ed meth­od, where­as TPA and CYFRA 21-1 ­were ­assayed by immu­nor­a­di­o­met­ric tech­niques. For ­each ­patient ­both the dis­mis­sion ­curve and the ­half-­life of con­sid­ered mark­ers ­were cal­cu­lat­ed dur­ing fol­low-up.
Results. A sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence was ­found for pre­op­er­a­tive val­ues of TPA (p=0.027) and CYFRA 21-1 (p=0.025) ­between SqCLC and aden­o­car­cin­o­ma. The pre­op­er­a­tive lev­els of mark­ers ­were high­er in ­patients ­who ­would devel­ope a ­relapse, ­even if sta­tis­tical sig­ni-f­i­cance was not ­reached. CEA ­half-­life was of 1.4 ­days, ­while in ­patients ­with a histo­ry of ­relapse or met­a­static spread­ing was 4.5 ­days. No dif­fer­enc­es ­were ­revealed con­cern­ing CYFRA 21-1 ­between the two ­groups.
Conclusions. Seriate deter­mi­na­tion of ­some mark­ers (CEA and TPA in par­tic­u­lar) dur­ing post­op­er­a­tive fol­low-up ­after sur­gery for bron­cho­gen­ic car­ci­no­mas can be a use­ful prog­nos­tic ­tool. Longer fol­low-up ­would pro­vide addi­tion­al infor­ma­tions in ­order to deter­mine indi­vid­u­al pre­dic­tive thres­hold ­between ­poor and ­good prog­no­sis.

top of page

Publication History

Cite this article as

Corresponding author e-mail